<?xml version='1.0' encoding='utf-8'?>
<document id="18176327"><sentence text="Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers."><entity charOffset="30-39" id="DDI-PubMed.18176327.s1.e0" text="lopinavir" /><entity charOffset="40-49" id="DDI-PubMed.18176327.s1.e1" text="ritonavir" /><entity charOffset="54-66" id="DDI-PubMed.18176327.s1.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.18176327.s1.e0" e2="DDI-PubMed.18176327.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s1.e0" e2="DDI-PubMed.18176327.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s1.e0" e2="DDI-PubMed.18176327.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s1.e1" e2="DDI-PubMed.18176327.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s1.e1" e2="DDI-PubMed.18176327.s1.e2" /></sentence><sentence text="This open-label, single-arm, pharmacokinetic (PK) study in HIV-seronegative volunteers evaluated the bioequivalence of rosuvastatin and lopinavir/ritonavir when administered alone and in combination"><entity charOffset="119-131" id="DDI-PubMed.18176327.s2.e0" text="rosuvastatin" /><entity charOffset="136-145" id="DDI-PubMed.18176327.s2.e1" text="lopinavir" /><entity charOffset="146-155" id="DDI-PubMed.18176327.s2.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18176327.s2.e0" e2="DDI-PubMed.18176327.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s2.e0" e2="DDI-PubMed.18176327.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s2.e0" e2="DDI-PubMed.18176327.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s2.e1" e2="DDI-PubMed.18176327.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s2.e1" e2="DDI-PubMed.18176327.s2.e2" /></sentence><sentence text=" Tolerability and lipid changes were also assessed" /><sentence text="" /><sentence text="Subjects took 20 mg of rosuvastatin alone for 7 days, then lopinavir/ritonavir alone for 10 days, and then the combination for 7 days"><entity charOffset="23-35" id="DDI-PubMed.18176327.s5.e0" text="rosuvastatin" /><entity charOffset="59-68" id="DDI-PubMed.18176327.s5.e1" text="lopinavir" /><entity charOffset="69-78" id="DDI-PubMed.18176327.s5.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18176327.s5.e0" e2="DDI-PubMed.18176327.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s5.e0" e2="DDI-PubMed.18176327.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s5.e0" e2="DDI-PubMed.18176327.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s5.e1" e2="DDI-PubMed.18176327.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s5.e1" e2="DDI-PubMed.18176327.s5.e2" /></sentence><sentence text=" Intensive PK sampling was performed on days 7, 17, and 24" /><sentence text="" /><sentence text="Twenty subjects enrolled, and PK data were available for 15 subjects" /><sentence text=" Geometric mean (+/-SD) rosuvastatin area under the concentration time curve (AUC)[0,tau] and maximum concentration (Cmax) were 47" /><sentence text="6 ng" /><sentence text="h/mL (+/-15" /><sentence text="3) and 4" /><sentence text="34 ng/mL (+/-1" /><sentence text="8), respectively, when given alone versus 98" /><sentence text="8 ng" /><sentence text="h/mL (+/-65" /><sentence text="5) and 20" /><sentence text="2 ng/mL (+/-16" /><sentence text="9) when combined with lopinavir/ritonavir (P &lt; 0"><entity charOffset="22-31" id="DDI-PubMed.18176327.s19.e0" text="lopinavir" /><entity charOffset="32-41" id="DDI-PubMed.18176327.s19.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18176327.s19.e0" e2="DDI-PubMed.18176327.s19.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s19.e0" e2="DDI-PubMed.18176327.s19.e1" /></sentence><sentence text="0001)" /><sentence text=" The geometric mean ratio was 2" /><sentence text="1 (90% confidence interval [CI]: 1" /><sentence text="7 to 2" /><sentence text="6) for rosuvastatin AUC[0,tau] and 4" /><sentence text="7 (90% CI: 3" /><sentence text="4 to 6" /><sentence text="4) for rosuvastatin Cmax with lopinavir/ritonavir versus rosuvastatin alone (P &lt; 0"><entity charOffset="7-19" id="DDI-PubMed.18176327.s27.e0" text="rosuvastatin" /><entity charOffset="30-39" id="DDI-PubMed.18176327.s27.e1" text="lopinavir" /><entity charOffset="40-49" id="DDI-PubMed.18176327.s27.e2" text="ritonavir" /><entity charOffset="57-69" id="DDI-PubMed.18176327.s27.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e0" e2="DDI-PubMed.18176327.s27.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e0" e2="DDI-PubMed.18176327.s27.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e0" e2="DDI-PubMed.18176327.s27.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e0" e2="DDI-PubMed.18176327.s27.e3" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e1" e2="DDI-PubMed.18176327.s27.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e1" e2="DDI-PubMed.18176327.s27.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e1" e2="DDI-PubMed.18176327.s27.e3" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e2" e2="DDI-PubMed.18176327.s27.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s27.e2" e2="DDI-PubMed.18176327.s27.e3" /></sentence><sentence text="0001)" /><sentence text=" There was 1 asymptomatic creatine phosphokinase elevation 17 times the upper limit of normal (ULN) and 1 liver function test elevation between 1" /><sentence text="1 and 2" /><sentence text="5 times the ULN with the combination" /><sentence text="" /><sentence text="Rosuvastatin low-density lipoprotein reduction was attenuated with lopinavir/ritonavir"><entity charOffset="0-12" id="DDI-PubMed.18176327.s33.e0" text="Rosuvastatin" /><entity charOffset="67-76" id="DDI-PubMed.18176327.s33.e1" text="lopinavir" /><entity charOffset="77-86" id="DDI-PubMed.18176327.s33.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18176327.s33.e0" e2="DDI-PubMed.18176327.s33.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s33.e0" e2="DDI-PubMed.18176327.s33.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s33.e0" e2="DDI-PubMed.18176327.s33.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s33.e1" e2="DDI-PubMed.18176327.s33.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s33.e1" e2="DDI-PubMed.18176327.s33.e2" /></sentence><sentence text=" Rosuvastatin AUC and Cmax were unexpectedly increased 2"><entity charOffset="1-13" id="DDI-PubMed.18176327.s34.e0" text="Rosuvastatin" /></sentence><sentence text="1- and 4" /><sentence text="7-fold in combination with lopinavir/ritonavir"><entity charOffset="27-36" id="DDI-PubMed.18176327.s36.e0" text="lopinavir" /><entity charOffset="37-46" id="DDI-PubMed.18176327.s36.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18176327.s36.e0" e2="DDI-PubMed.18176327.s36.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s36.e0" e2="DDI-PubMed.18176327.s36.e1" /></sentence><sentence text=" Rosuvastatin and lopinavir/ritonavir should be used with caution until the safety, efficacy, and appropriate dosing of this combination have been demonstrated in larger populations"><entity charOffset="1-13" id="DDI-PubMed.18176327.s37.e0" text="Rosuvastatin" /><entity charOffset="18-27" id="DDI-PubMed.18176327.s37.e1" text="lopinavir" /><entity charOffset="28-37" id="DDI-PubMed.18176327.s37.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18176327.s37.e0" e2="DDI-PubMed.18176327.s37.e0" /><pair ddi="false" e1="DDI-PubMed.18176327.s37.e0" e2="DDI-PubMed.18176327.s37.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s37.e0" e2="DDI-PubMed.18176327.s37.e2" /><pair ddi="false" e1="DDI-PubMed.18176327.s37.e1" e2="DDI-PubMed.18176327.s37.e1" /><pair ddi="false" e1="DDI-PubMed.18176327.s37.e1" e2="DDI-PubMed.18176327.s37.e2" /></sentence><sentence text="" /></document>